New combo therapy aims to fight rare nasal cancer before surgery
NCT ID NCT07614828
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether giving immunotherapy (Toripalimab) and chemotherapy (Temozolomide) before surgery can improve outcomes for people with a rare type of melanoma in the nasal cavity. The study will enroll 25 participants with resectable tumors. The main goal is to see if this approach can delay or prevent the cancer from spreading to other parts of the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Toripalimab (immunotherapy) and Temozolomide (chemotherapy)
- What this could lead to
- If successful, this approach could improve survival and reduce cancer spread in people with a rare and aggressive nasal melanoma.
- What could go wrong
- This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The combination of treatments may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOSAL MELANOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eye & ENT Hospital
Shanghai, Shanghai Municipality, 200030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.